Ryotaro Nakamura, MD, City of Hope, Duarte, CA, gives an overview of some exciting research being conducted in the field of myelodysplastic syndromes (MDS), emphasizing the value of studies which aim to provide a better understanding of the underlying biology and heterogeneity of MDS. Dr Nakamura then comments on the promise of novel immunotherapeutic agents and treatment approaches in MDS. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.